Citations

Mayo Clinic

Showing 10 of 108537 citations.

Improvement in Accuracy and Concordance of American Society of Anesthesiologist’s Physical Status (ASA-PS) Scoring Assignment over a 11 Year Time Period Using Patient BMI as a Comorbidity Finding
Dyer, Matthew W., Kor, Benjamin T. , Kor, Nathan T., Hanson, Andrew C. , Kor, Jennifer J., Kor, Todd M. , Stewart, Thomas M. , Sviggum, Hans P.

Anesthesiology Research and Practice | May 23, 2024 | Volume: 2024 | Issue: No issue available | Pages: 1-6

10.1155/2024/6989174 | PMID 38813264 Get It

Background. Anesthesia providers categorize patients utilizing the American Society of Anesthesiologists Physical Status (ASA-PS) classification originally created by the ASA in 1941. There is published variability and discordance among providers when assigning patient ASA scores in part due to the subjectivity of scoring utilizing patient medical conditions, but variability is also found using objective findings like BMI. To date, there are few studies evaluating the accuracy of anesthesia providers’ ASA assignment based on objective body mass index (BMI) alone. The aim of this retrospective chart review is to determine improvement in accuracy of anesthesia providers to correctly assign patient ASA scores, based on BMI criteria added to the ASA-PS in October of 2014, utilizing a multifaceted strategy including creation of an active finance committee in the fall of 2015, multiple e-mail communications about the updated definitions and recommendations for ASA-PS scoring in the fall of 2015 and spring of 2016, a department grand rounds presentation in February 2016, placement of laminated copies of the ASA definitions and recommendations in the anesthesia chartrooms, and the development of a tool embedded into our EMR providing a recommendation of ASA-PS based on patient comorbidity findings. Methods. After attaining IRB approval, all eligible patients over the age of 18 who had surgical procedures under general anesthesia at Mayo Clinic in Rochester, MN, between January 1, 2010, and December 31, 2020, were retrospectively analyzed. A segmented logistic regression model was used to estimate the trends (per-year change in odds) of ASA under classification according to severity of obesity during 3 epochs: preimplementation (2010–2014), implementation (2015), and postimplementation (2016–2020). Results. A total of 16,467 patients of the 200,423 (8.2%) patients with obesity (class 1, 2, and 3) were underscored based on BMI alone. Accuracy of ASA-PS classification, as it pertains to BMI alone, was found to show meaningful improvement year-to-year following the updated ASA-PS guidelines with examples released in October of 2014 (P<0.001). Most of the improvement occurred in 2015–2017 with relatively little between-year variability in the rate of underscoring from 2017–2020. Conclusion. Despite updated ASA-PS published guidelines, providers may still be unaware of the updated guidelines and inclusion of examples used within the ASA-PS classification system. Accuracy of scoring did improve annually following the release of the updated guidelines with examples as well as department-wide educational activities on the topic. Additional education and awareness should be offered to those responsible for preanesthesia evaluation and assignment of ASA-PS in patients to improve accuracy as it pertains to BMI.
Cost-effectiveness of population screening for aortic stenosis
Motazedian, Pouya, Hibbert, Benjamin , Jalal, Hawre , Labinaz, Marino , Burwash, Ian G. , Abdel‐Razek, Omar , Santo, Pietro Di , Wells, George A. , Hibbert, Benjamin , Jalal, Hawre , Abdel-Razek, Omar , Wells, George , Motazedian, Pouya , Prosperi‐Porta, Graeme , Simard, Trevor , Coyle, Doug

European Heart Journal - Quality of Care and Clinical Outcomes | May 23, 2024 | Volume: 11 | Issue: 4 | Pages: 378-387

10.1093/ehjqcco/qcae043 | PMID 38777625 Get It

Abstract Aims Aortic stenosis (AS) is a progressive disease predominantly affecting elderly patients that carries significant morbidity and mortality without aortic valve replacement, the only proven treatment. Our objective was to determine the cost-effectiveness of AS screening using transthoracic echocardiography (TTE) in a geriatric population from the perspective of the publicly funded healthcare system in Canada. Methods and results Markov models estimating the cost-effectiveness ratio (ICER) for AS screening with a one-time TTE were developed. The model included diagnosed and undiagnosed AS health states, hospitalizations, transcatheter aortic valve replacement (TAVR), and post-TAVR health states. Primary analysis included screening at 70 and 80 years of age with intervention at symptom onset, with scenario analysis included for early intervention at the time of severe asymptomatic AS diagnosis. Monte Carlo simulation of 5000 replications was completed with a lifetime horizon and a 1.5% discount for costs and outcomes.Screening for AS at the age of 70 years was associated with an ICER of $156 722, and screening at 80 years of age was associated with an ICER of $28 005, suggesting that screening at 80 years of age is cost-effective when willingness-to-pay per QALY is $50 000. Scenario analysis with early intervention was not cost-effective, with an ICER of $142 157 at 70 years and $124 651 at 80 years. Conclusion Screening for AS at 80 years of age with a one-time TTE, in a Canadian population, improves quality of life and is cost-effective in a publicly funded healthcare system providing, TAVR is reserved for symptomatic patients.
Liver function and portal‐systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices
Hassanein, Tarek , Keaveny, Andrew P. , Mantry, Parvez , McRae, Michael P. , Kittelson, John, Helmke, Steve M. , Everson, Gregory T. , Investigators, for the SHUNT‐V, McRae, Michael P , Everson, Gregory T , Keaveny, Andrew P , Smith, Alastair D. , Investigators, for the SHUNT‐V

Alimentary Pharmacology & Therapeutics | May 23, 2024 | Volume: 60 | Issue: 2 | Pages: 246-256

10.1111/apt.18054 | PMID 38778481 Get It

Summary Background The quantitative HepQuant SHUNT test of liver function and physiology generates a disease severity index (DSI) that correlates with risk for clinical complications, such as large oesophageal varices (LEVs). A derivative test, HepQuant DuO, generates an equivalent DSI and simplifies testing by requiring only oral administration of the test solution and two blood samples at 20 and 60 min. Aims Since the DSIs measured from DuO and SHUNT are equivalent, we compared the diagnostic performance for large oesophageal varices (LEVs) between the DSIs measured from DuO and SHUNT tests. Methods This study combined the data from two prospectively conducted US studies: HALT‐C and SHUNT‐V. A total of 455 subjects underwent both the SHUNT test and esophagogastroduodenoscopy (EGD). Results DSI scores correlated with the probability of LEVs ( p < 0.001) and demonstrated a stepwise increase from healthy lean controls without liver disease to subjects with chronic liver disease and no, small or large varices. Furthermore, a cutoff of DSI ≤ 18.3 from DuO had a sensitivity of 0.98 (missing only one case) and, if applied to the endoscopy (EGD) decision, would have prevented 188 EGDs (41.3%). The AUROC for DSI from DuO did not differ from that of the reference SHUNT test method (0.82 versus 0.81, p = 0.3500). Conclusions DSI from HepQuant DuO links liver function and physiology to the risk of LEVs across a wide spectrum of patient characteristics, disease aetiologies and liver disease severity. DuO is minimally invasive, easy to administer, quantitative and may aid the decision to avoid or perform EGD for LEVs.
Exploring the Prevalence of Urinary Incontinence in Multi-Ethnic Refugee Women in Maricopa County, Arizona
Malekian, Sheila, Fawcett, Lubayna, Khan, Aqsa , Adeleye, Olufunmilola

No container title available | May 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4414573/v1 Get It

Abstract This study explores the prevalence of urinary incontinence among multi-ethnic refugee women and their comfort levels in discussing this topic with their healthcare providers. Between July and November 2021, 58 refugee women were recruited within community spaces using convenience sampling and word-of-mouth. They completed a 20-item questionnaire in Arabic, Burmese, Swahili, or Somali. Urinary incontinence was identified by an affirmative response to any of the 6-item Urogenital Distress Inventory questions or the report of at least one episode of stress or urgency incontinence per month. The observed prevalence of urinary incontinence in this cohort was 50%. Despite 59.6% of participants expressing comfort in discussing these symptoms, 82.8% of them revealed that they had never spoken with a healthcare provider about them. Moreover, 77.6% of these women reported never being queried about these symptoms by a healthcare professional. Based on these results, urinary incontinence is notably prevalent among refugee women, either surpassing or at least aligning with the prevalence observed in the general female population. Healthcare professionals serving refugee women should consider incorporating screening for this condition into routine office visits. Notably, the limited sample size of this study underscores the necessity for further research on this subject.
Suicide Risk Screening for Head and Neck Cancer Patients: An Implementation Study
Kansara, Bhargav, Basta, Ameer , Mikhael, Marian, Perkins, Randa, Reisman, Phillip , Rollison, Dana E. , Nguyen, Oliver T. , Gilbert, Scott M. , Hallanger-Johnson, Julie, Mikhael, Marian, Hallanger‐Johnson, Julie , Powell, Sean, Turner, Kea L.

Applied Clinical Informatics | May 22, 2024 | Volume: 15 | Issue: 02 | Pages: 404-413

10.1055/s-0044-1787006 | PMID 38777326 Get It

Abstract Objectives There is limited research on suicide risk screening (SRS) among head and neck cancer (HNC) patients, a population at increased risk for suicide. To address this gap, this single-site mixed methods study assessed oncology professionals' perspectives about the feasibility, acceptability, and appropriateness of an electronic SRS program that was implemented as a part of routine care for HNC patients. Methods Staff who assisted with SRS implementation completed (e.g., nurses, medical assistants, advanced practice providers, physicians, social workers) a one-time survey (N = 29) and interview (N = 25). Quantitative outcomes were assessed using previously validated feasibility, acceptability, and appropriateness measures. Additional qualitative data were collected to provide context for interpreting the scores. Results Nurses and medical assistants, who were directly responsible for implementing SRS, reported low feasibility, acceptability, and appropriateness, compared with other team members (e.g., physicians, social workers, advanced practice providers). Team members identified potential improvements needed to optimize SRS, such as hiring additional staff, improving staff training, providing different modalities for screening completion among individuals with disabilities, and revising the patient-reported outcomes to improve suicide risk prediction. Conclusion Staff perspectives about implementing SRS as a part of routine cancer care for HNC patients varied widely. Before screening can be implemented on a larger scale for HNC and other cancer patients, additional implementation strategies may be needed that optimize workflow and reduce staff burden, such as staff training, multiple modalities for completion, and refined tools for identifying which patients are at greatest risk for suicide.
Health equity engineering: Optimizing hope for a new generation of healthcare
Enders, Felicity , Brooks, Tayla R., Carr, Allison R. , Cullen, John P. , DiazGranados, Deborah , Gaba, Ayorkor , Johnson, Leigh , Messinger, Shari , Milam, Adam J. , Perkins, Susan M. , Pineda, Tiffany Danielle , Periyakoil, Vyjeyanthi S. , Hanlon, Alexandra L. , Enders, Felicity T , Golembiewski, Elizabeth H , Cullen, John P , DiazGranados, Deborah , Gaba, Ayorkor , Orellana, Minerva A , Pineda, Tiffany D Chisholm , Milam, Adam J , Messinger, Shari , Golembiewski, Elizabeth H. , Balls‐Berry, Joyce E. , Brooks, Tayla Rashanaye , Menser, Terri , Orellana, Minerva , Thurston, Sally W.

Journal of Clinical and Translational Science | May 22, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1017/cts.2024.549 | PMID 39478773 Get It

Abstract Medical researchers are increasingly prioritizing the inclusion of underserved communities in clinical studies. However, mere inclusion is not enough. People from underserved communities frequently experience chronic stress that may lead to accelerated biological aging and early morbidity and mortality. It is our hope and intent that the medical community come together to engineer improved health outcomes for vulnerable populations. Here, we introduce Health Equity Engineering (HEE), a comprehensive scientific framework to guide research on the development of tools to identify individuals at risk of poor health outcomes due to chronic stress, the integration of these tools within existing healthcare system infrastructures, and a robust assessment of their effectiveness and sustainability. HEE is anchored in the premise that strategic intervention at the individual level, tailored to the needs of the most at-risk people, can pave the way for achieving equitable health standards at a broader population level. HEE provides a scientific framework guiding health equity research to equip the medical community with a robust set of tools to enhance health equity for current and future generations.
A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer
Mosalem, Osama , Coston, Tucker , Imperial, Robin John Lester , Mauer, Elizabeth , Thompson, Christopher, Bekaii-Saab, Tanios S , Stoppler, Melissa C. , Starr, Jason S. , Bekaii‐Saab, Tanios , Coston, Tucker W , Imperial, Robin , Bekaii-Saab, Tanios S , Starr, Jason , Bekaii-Saab, Tanios S , Mosalem, Osama M , Yilma, Binyam

The Oncologist | May 22, 2024 | Volume: 29 | Issue: 9 | Pages: e1224-e1227

10.1093/oncolo/oyae098 | PMID 38776551 Get It

Abstract Introduction Pathogenic mutations in POLE/POLD1 lead to decreased fidelity of DNA replication, resulting in a high tumor mutational burden (TMB-H), defined as TMB ≥ 10 mut/Mb, independent of deficient mismatch repair (dMMR) and microsatellite instability high (MSI-H) status. Methods De-identified records of patients with colorectal cancer (CRC) profiled with the Tempus xT assay (DNA-seq of 595-648 genes at 500×) were identified from the Tempus Database. Results Among 9136 CRC samples profiled, the frequency of POLE/POLD1 genomic alterations was 2.4% (n = 217). Copy number loss was the most common genomic alteration (64%, n = 138) of POLE/POLD1, followed by copy number amplifications (18%, n = 40) and short variant mutations (18%, n = 39). The POLE/POLD1 mutated group presented with a higher frequency of TMB-H phenotype relative to wild type (WT; 22% vs. 9%, P &lt; .001), with a median TMB of 127 mut/Mb in the TMB-H POLE/POLD1 subset. The TMB showed a dramatic contrast between POLE/POLD1 short variant mutations as compared to the group with copy number alterations, with a TMB of 159 mut/Mb vs 15 mut/Mb, respectively. Thus, the short variant mutations represented the so-called ultra-hypermutated phenotype. The POLE/POLD1 mutated group, as compared to WT, exhibited a higher rate of coexisting mutations, including APC, ALK, ATM, BRCA2, and RET mutations. Conclusion Patients with POLE/POLD1 mutations exhibited significant differences across immunological markers (ie, TMB, MMR, and MSI-H) and molecular co-alterations. Those with short variant mutations represented 18% of the POLE/POLD1 cohort and 0.4% of the total cohort examined. This group of patients had a median TMB of 159 mut/Mb (range 34-488), representing the ultra-hypermutated phenotype. This group of patients is important to identify given the potential for exceptional response to immune checkpoint inhibitors.
Launching an International Community of Practice in Hematology/Oncology Medical Education
Walsh, Katherine, Schwartz, Jennifer, Brondfield, Sam , Manochakian, Rami

American Society of Clinical Oncology Educational Book | May 22, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1200/edbk_100046 | PMID 38776483 Get It

A community of practice (CoP) is a group of people who share a concern or a passion for something they do and learn how to do it better as they interact regularly. While the field of hematology/oncology has historically prioritized clinical care and biomedical research, medical education has received increasing attention within hematology/oncology in recent years. In 2018, ASCO launched the Education Scholars Program to train hematology/oncology clinicians in the science of teaching and learning. However, the number of hematology/oncology educators nationally and internationally far exceeds the capacity of the Education Scholars Program to train them. In addition, hematology/oncology educators often lack sufficient mentorship and guidance at their own institutions to pursue their chosen career path effectively. To ensure high-quality clinical care and research for generations to come, attention must be paid to improving support for hematology/oncology educators. Therefore, supported by ASCO, we developed an international medical education (Med Ed) CoP for hematology/oncology educators with the purpose of providing them with support, community, mentorship, resources, and scholarly opportunities in medical education. In this article, we describe the development of the Med Ed CoP using a three-stage framework (Establish-Grow-Sustain) including successes, challenges, and reflections. By supporting the needs of hematology/oncology educators, the Med Ed CoP will serve as a home for all who contribute to the field of hematology/oncology.
Head Up Position CPR: A Complementary Option for Out-of-Hospital Cardiac Arrest
Lurie, Keith G. , Moore, Johanna , Goodloe, Jeffrey M. , Holley, Joe , Porter, Randy, Campensa, Ross, Bachista, Kerry, Goodloe, Jeffrey

Prehospital Emergency Care | May 22, 2024 | Volume: 28 | Issue: 5 | Pages: 748-750

10.1080/10903127.2024.2359506 | PMID 38776428 Get It

Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome
Corriveau‐Lecavalier, Nick , Botha, Hugo , Graff‐Radford, Jonathan , Przybelski, Scott A. , Wiste, Heather J. , Murray, Melissa E. , Reichard, R. Ross , Dickson, Dennis W. , Nguyen, Aivi T. , Fields, Julie A. , Nelson, Peter T. , Lowe, Val J. , Petersen, Ronald C. , Jack, Clifford R. , Switzer, Aaron R , Murray, Melissa E , Reichard, Robert Ross, Dickson, Dennis W , Ramanan, Vijay K , Boeve, Brad , Stricker, Nikki H. , Grothe, Michel J , Knopman, David S. , Jack, Clifford R , Jones, David T , Botha, Hugo , Nguyen, Aivi T , Corriveau-Lecavalier, Nick , Switzer, Aaron , Ramanan, Vijay K. , McCarter, Stuart J. , Boeve, Bradley F. , Machulda, Mary M. , Grothe, Michel J. , Knopman, David S. , Jones, David T.

Brain Communications | May 22, 2024 | Volume: 6 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcae183 | PMID 39021510 Get It

Abstract Predominant limbic degeneration has been associated with various underlying aetiologies and an older age, predominant impairment of episodic memory and slow clinical progression. However, the neurological syndrome associated with predominant limbic degeneration is not defined. This endeavour is critical to distinguish such a syndrome from those originating from neocortical degeneration, which may differ in underlying aetiology, disease course and therapeutic needs. We propose a set of clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome that is highly associated with limbic-predominant age-related TDP-43 encephalopathy but also other pathologic entities. The criteria incorporate core, standard and advanced features, including older age at evaluation, mild clinical syndrome, disproportionate hippocampal atrophy, impaired semantic memory, limbic hypometabolism, absence of neocortical degeneration and low likelihood of neocortical tau, with degrees of certainty (highest, high, moderate and low). We operationalized this set of criteria using clinical, imaging and biomarker data to validate its associations with clinical and pathologic outcomes. We screened autopsied patients from Mayo Clinic and Alzheimer’s Disease Neuroimaging Initiative cohorts and applied the criteria to those with an antemortem predominant amnestic syndrome (Mayo, n = 165; Alzheimer’s Disease Neuroimaging Initiative, n = 53) and who had Alzheimer’s disease neuropathological change, limbic-predominant age-related TDP-43 encephalopathy or both pathologies at autopsy. These neuropathology-defined groups accounted for 35, 37 and 4% of cases in the Mayo cohort, respectively, and 30, 22 and 9% of cases in the Alzheimer’s Disease Neuroimaging Initiative cohort, respectively. The criteria effectively categorized these cases, with Alzheimer’s disease having the lowest likelihoods, limbic-predominant age-related TDP-43 encephalopathy patients having the highest likelihoods and patients with both pathologies having intermediate likelihoods. A logistic regression using the criteria features as predictors of TDP-43 achieved a balanced accuracy of 74.6% in the Mayo cohort, and out-of-sample predictions in an external cohort achieved a balanced accuracy of 73.3%. Patients with high likelihoods had a milder and slower clinical course and more severe temporo-limbic degeneration compared to those with low likelihoods. Stratifying patients with both Alzheimer’s disease neuropathological change and limbic-predominant age-related TDP-43 encephalopathy from the Mayo cohort according to their likelihoods revealed that those with higher likelihoods had more temporo-limbic degeneration and a slower rate of decline and those with lower likelihoods had more lateral temporo-parietal degeneration and a faster rate of decline. The implementation of criteria for a limbic-predominant amnestic neurodegenerative syndrome has implications to disambiguate the different aetiologies of progressive amnestic presentations in older age and guide diagnosis, prognosis, treatment and clinical trials.